The pharmaceutical giant that misled physicians and patients about the addictive properties of its top-selling drug OxyContin, fuelling an overdose crisis that has devastated communities across North America, will stop marketing opioids to U.S. physicians.
However, the new policy does not extend into Canada.
Purdue Pharma L.P. announced the change in a statement issued on the weekend.
Read more at The Globe and Mail
Leave a Reply